Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws

Journal of Oral Pathology and Medicine

Volumn 40, Issue 6, 2011, Pages 510-515

  Arduino, P G ^a   Menegatti, E ^a   Scoletta, M ^a   Battaglio, C ^a   Mozzati, M ^a   Chiecchio, A ^a   Berardi, D ^a   Vandone, A M ^b   Donadio, M ^b   Gandolfo, S ^a   Scully, C ^c   Broccoletti, R ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bisphosphonate; Gene polymorphisms; Osteonecrosis; VEGF

Indexed keywords

VASCULOTROPIN; ZOLEDRONIC ACID;

5' UNTRANSLATED REGION; ARTICLE; BISPHOSPHONATE RELATED JAW OSTEONECROSIS; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG INDUCED DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; JAW OSTEONECROSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; DIPHOSPHONATES; FEMALE; HAPLOTYPES; HUMANS; IMIDAZOLES; JAW DISEASES; MULTIPLE MYELOMA; ODDS RATIO; OSTEONECROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959975670     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.01004.x     Document Type: Article

References (28)

1. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93.
2. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91.
3. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effect of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine 1997; 76: 266-83.
4. Devogelaer P. Treatment of bone diseases with bisphosphonates, excluding osteoporosis. Curr Opin Rheumatol 2000; 12: 331-5.
5. Bagan J, Scully C, Sabatier V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): a concise update. Oral Oncol 2009; 45: 551-4.
6. Hewit C, Farah CS. Bisphosphonate-related osteonecrosis of the jaw: a comprehensive review. J Oral Pathol Med 2007; 36: 319-28.
7. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonates therapy. J Dent Res 2007; 86: 1013-21.
8. Raikkonen J, Monkkonen H, Auriol S, Monkkonen J. Mevalonate pathway intermediates downregulate zoledronic acid-induced insolently pyrophosphate and ATP analogy formation in human breast cancer cells. Biochem Pharmacol 2010; 79: 777-83.
9. Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003; 14: 1468-76.
10. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005; 69: 35-43.
11. Keyt B, Berleau L, Nguyen H, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-95.
12. Dai J, Rabies AB. VEGF: an essential mediator of both angiogenesis and endochondral ossification. J Dent Res 2007; 86: 937-50.
13. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphism within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-5.
14. Renner W, Kitchen S, Hoffman C, Obermayer-Pietsch B, Pilfer E. A common 936 C/T mutation in the gene for vascular endothelial growth factors is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443-8.
15. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphism in the promoter and 5' UTR regions of human vascular endothelial growth factor gene. Hum Immunol 1999; 60: 1245-9.
16. Kim TH, Hong JM, Lee JY, et al. Promoter polymorphisms of the vascular endothelial growth factor gene is associated with an osteonecrosis of the femoral head in the Korean population. Osteoarthritis Cartilage 2008; 16: 287-91.
17. Fedele S, Porter SR, D'Aiuto F, et al. Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 2010; 123: 1060-4.
18. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999; 14: 143-9.
19. Sarasquete ME, García-Sanz R, Marín L, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008; 112: 2709-12.
20. Costa N, Paramanathan S, Mac Donald D, Wierzbicki AS, Hampson G. Factors regulating circulating vascular endothelial growth factor (VEGF): association with bone mineral density (BMD) in post-menopausal osteoporosis. Cytokine 2009; 46: 376-81.
21. Awata T, Inoue K, Kurihara S, et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type-2 diabetes. Diabetes 2002; 51: 1635-9.
22. Shahbazi M, Fryer AA, Pravica V, et al. Vascular Endothelial Growth Factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260-4.
23. Schipani E, Ryan HE, Didrickson S, Kobayashi Tm, Knight M, Johnson RS. Hypoxia in cartilage: HIF-1 alpha is essential for chondrocyte growth arrest and survival. Genes Dev 2001; 15: 2865-76.
24. Komatsu DE, Hadijardyrou M. Activation of transcription factor HIF-1 and its target genes, VEGF, HO-1, iNOS, during fracture repair. Bone 2004; 34: 680-8.
25. Street J, Bao M, deGuzman L, et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc Natl Acad Sci U S A 2002; 99: 9656-61.
26. Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest 2002; 110: 751-9.
27. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G III, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008; 26: 4037-8.
28. Maahs MP, Azambuja AA, Campos MM, Salum FG, Cherubini K. Association between bisphosphonates and jaw osteonecrosis: a study in Wistar rats. Head Neck 2010. [Epub ahead of print]